Published On: Mon, Mar 20th, 2017

Analysts Watch Zoetis Inc. (NYSE:ZTS) And Issue New Targets


Recently stock market analysts have updated their consensus ratings on shares of Zoetis Inc. (NYSE:ZTS).

Most recent broker ratings

03/15/2017 – Craig-Hallum began new coverage on Zoetis Inc. giving the company a “buy” rating. They now have a USD 65 price target on the stock.

02/17/2017 – Zoetis Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 60 price target on the stock.

02/16/2017 – Zoetis Inc. had its “buy” rating reiterated by analysts at Guggenheim. They now have a USD 65 price target on the stock.

02/13/2017 – Zoetis Inc. had its “strong sell” rating reiterated by analysts at Off Wall Street. They now have a USD 35 price target on the stock.

01/20/2017 – Zoetis Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 64 price target on the stock.

12/20/2016 – Deutsche Bank began new coverage on Zoetis Inc. giving the company a “buy” rating. They now have a USD 62 price target on the stock.

12/15/2016 – Zoetis Inc. was upgraded to “outperform” by analysts at Cowen. They now have a USD 60 price target on the stock.

12/15/2016 – Piper Jaffray began new coverage on Zoetis Inc. giving the company a “overweight” rating. They now have a USD 61 price target on the stock.

10/11/2016 – Zoetis Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 58 price target on the stock.

09/29/2016 – Zoetis Inc. had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 60 price target on the stock.

09/09/2016 – Zoetis Inc. had its “buy” rating reiterated by analysts at Argus. They now have a USD 58 price target on the stock.

09/07/2016 – Zoetis Inc. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 60 price target on the stock.

06/10/2016 – Zoetis Inc. was downgraded to “neutral” by analysts at Citigroup. They now have a USD 50 price target on the stock.

05/06/2016 – Zoetis Inc. was downgraded to “sell” by analysts at Goldman Sachs. They now have a USD 48 price target on the stock.

01/08/2016 – Cleveland Research began new coverage on Zoetis Inc. giving the company a “buy” rating.

Zoetis Inc. has a 50 day moving average of 54.25 and a 200 day moving average of 52.11. The stock’s market capitalization is 26.68B, it has a 52-week low of 39.80 and a 52-week high of 56.50.

The share price of the company (NYSE:ZTS) was up +0.44%, with a high of 54.45during the day and the volume of Zoetis Inc. shares traded was 1400392.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company’s segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.